Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.31 +0.10 (+0.86%)
Streaming Delayed Price Updated: 12:09 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 655,429
Open 12.28
Bid (Size) 12.31 (10)
Ask (Size) 12.32 (6)
Prev. Close 12.21
Today's Range 12.20 - 12.38
52wk Range 3.555 - 12.52
Shares Outstanding 56,434,219
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
From Brodsky & Smith LLC
Via GlobeNewswire
Unusual volume stocks in Monday's session
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill

Performance

YTD
+37.3%
+37.3%
1 Month
+64.0%
+64.0%
3 Month
+84.4%
+84.4%
6 Month
+136.8%
+136.8%
1 Year
+4.8%
+4.8%

More News

Read More
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates RYN, PCH, ATXS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play
Via Stocktwits
BioCryst To Acquire Astria Therapeutics In $700M Deal
Via Stocktwits
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
From Brodsky & Smith LLC
Via GlobeNewswire
This Verisk Analytics Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
Via Benzinga
Which stocks are gapping on Tuesday?
Via Chartmill
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
Via Chartmill
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Astria Therapeutics, Inc. - Common Stock publicly traded?
Yes, Astria Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Astria Therapeutics, Inc. - Common Stock trade on?
Astria Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Astria Therapeutics, Inc. - Common Stock?
The ticker symbol for Astria Therapeutics, Inc. - Common Stock is ATXS on the Nasdaq Stock Market
What is the current price of Astria Therapeutics, Inc. - Common Stock?
The current price of Astria Therapeutics, Inc. - Common Stock is 12.31
When was Astria Therapeutics, Inc. - Common Stock last traded?
The last trade of Astria Therapeutics, Inc. - Common Stock was at 10/23/25 12:09 PM ET
What is the market capitalization of Astria Therapeutics, Inc. - Common Stock?
The market capitalization of Astria Therapeutics, Inc. - Common Stock is 694.99M
How many shares of Astria Therapeutics, Inc. - Common Stock are outstanding?
Astria Therapeutics, Inc. - Common Stock has 695M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.